However, PSMA expression exhibits significant intra- and inter-tumor heterogeneity in advanced PCa [62,63,64], as also highlighted by recent preclinical and clinical studies demonstrating that not all patients with PSMA-positive PCa respond to PSMA-targeted radionuclide 177Lu-PSMA-617 [65]. Here, FOLH1 is linked to neoplasm.